Showing results (401-410 of 439) with videos related to

Sort By:
Pageof 44
Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.
Blood Cancer Journal|August 8, 2025
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohortsPatrizia Mondello, Brianna Negaard, Andrew L Feldman, et al.
Cancer Cell|September 8, 2025
Large B cell lymphoma microenvironment archetype profilesXubin Li, Kartik Singhal, Qing Deng, et al.
Blood Advances|February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort StudyJia Ruan, Zhengming Chen, Melissa C Larson, et al.
American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.
Cell Reports. Medicine|November 17, 2022
A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphomaJohannes F Fahrmann, Neeraj Y Saini, Chang Chia-Chi, et al.
Blood Advances|July 15, 2021
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicityUri Greenbaum, Paolo Strati, Rima M Saliba, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J Nastoupil, Clark R Andersen, Amy Ayers, et al.
European Journal of Haematology|May 11, 2021
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survivalKrithika Shanmugasundaram, Subir Goyal, Jeffery Switchenko, et al.
American Journal of Hematology|July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab eraReem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
Pageof 44